A Case Report of Gynecomastia Due to Rosuvastatin
10.21215/kjfp.2019.9.5.471
- Author:
Joon Hoon JEONG
1
;
Yun Seong KIM
;
Sang Kwon LEE
Author Information
1. Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
- Publication Type:Case Report
- Keywords:
Gynecomastia;
Drug-Related Side Effects and Adverse Reactions;
Rosuvastatin Calcium
- MeSH:
Anxiety;
Breast;
Drug-Related Side Effects and Adverse Reactions;
Estrogens;
Gynecomastia;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Male;
Middle Aged;
Rosuvastatin Calcium
- From:
Korean Journal of Family Practice
2019;9(5):471-474
- CountryRepublic of Korea
- Language:English
-
Abstract:
Gynecomastia is a common benign disease characterized by the progressive enlargement of the glandular tissue of the male breast due to an imbalance between the levels of estrogen and androgen in the blood. The etiology may vary and may be physiological, pharmacological, pathological, or even idiopathic. Among men, drug-induced gynecomastia may account for 10% to 20% of cases. The literature contains six case reports of rosuvastatin-induced gynecomastia. Withdrawal of statin or switching to a less potent statin can lead to symptom improvement and avoidance of unnecessary tests and patient anxiety. A 62-year-old male patient developed unilateral gynecomastia after 13 months of rosuvastatin therapy. After switching to a different statin (pravastatin), his symptoms improved within 2 months. Thus, clinicians should be aware of the possibility of occurrence of gynecomastia when statins are prescribed.
